Praxis (PRAX) Gains After FDA Grants Breakthrough Therapy Designation for Elsunersen

Praxis Precision Medicines (PRAX) shares rose after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its investigational drug, Elsunersen. The designation targets the treatment of pediatric patients with SCN2A-developmental and epileptic encephalopathy (SCN2A-DEE). The FDA's Breakthrough Therapy Designation aims to accelerate the development and review of drugs for serious conditions, based on preliminary clinical evidence suggesting substantial improvement over existing therapies. Elsunersen is an antisense oligonucleotide (ASO) engineered to reduce the expression of the SCN2A gene. This designation offers Praxis enhanced FDA guidance, including advice on clinical trial design, and eligibility for priority review and accelerated approval. SCN2A-DEE is a severe genetic disorder characterized by early-onset epilepsy and significant developmental delays.